Pharmacogenetics of olanzapine metabolism

Pharmacogenomics

Volumn 14, Issue 11, 2013, Pages 1319-1336

  Söderberg, Mao Mao ^a   Dahl, Marja Liisa ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

AHR; CYP1A2; CYP2D6; CYP3A43; FMO1; FMO3; olanzapine; single nucleotide polymorphism; UGT1A4; UGT2B10

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; CYTOCHROME P450 3A43; DIMETHYLANILINE MONOOXYGENASE; FMO1 PROTEIN; FMO3 PROTEIN; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A4; GLUCURONOSYLTRANSFERASE 2B10; OLANZAPINE; UNCLASSIFIED DRUG; BENZODIAZEPINE DERIVATIVE; BILIRUBIN GLUCURONOSIDE GLUCURONOSYLTRANSFERASE; CYP1A1 PROTEIN, HUMAN; DIMETHYLANILINE MONOOXYGENASE (N-OXIDE FORMING); OXYGENASE; UGT2B10 PROTEIN, HUMAN;

AREA UNDER THE CURVE; BIPOLAR DISORDER; DEMETHYLATION; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG MONITORING; ENZYME ACTIVITY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOTE; HUMAN; MAXIMUM PLASMA CONCENTRATION; PHARMACOGENETICS; REVIEW; SCHIZOPHRENIA; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; TIME TO MAXIMUM PLASMA CONCENTRATION; BLOOD; DRUG INACTIVATION; FEMALE; GENETICS; METABOLISM;

BENZODIAZEPINES; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2D6; FEMALE; GLUCURONOSYLTRANSFERASE; HUMANS; INACTIVATION, METABOLIC; OXYGENASES; PHARMACOGENETICS;

EID: 84882240094     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.120     Document Type: Review

References (83)

1. Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353, 1209-1223 (2005).
2. Lewis S, Barnes T, Murray R et al. First generation versus second generation (non-clozapine) antipsychotic drugs versus clozapine in schizophrenia: the CUtLASS trials. Neuropsychopharmacology 30, S31-S32 (2005).
3. Kahn RS, Fleischhacker WW, Boter H et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371, 1085-1097 (2008).
4. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373, 31-41 (2009).
5. De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat. Rev. Endocrinol. 8, 114-126 (2012).
6. Kapur S, Zipursky RB, Remington G et al. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am. J. Psychiatry 155, 921-928 (1998).
7. Nordstrom AL, Farde L, Wiesel FA et al. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol. Psychiatry 33, 227-235 (1993).
8. Hiemke C, Baumann P, Bergemann N et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 44, 195-235 (2011).
9. Kinon BJ, Volavka J, Stauffer V et al. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study. J. Clin. Psychopharmacol. 28, 392-400 (2008).
10. Skogh E, Reis M, Dahl ML, Lundmark J, Bengtsson F. Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting. Ther. Drug Monit. 24, 518-526 (2002).
11. Bigos KL, Bies RR, Pollock BG, Lowy JJ, Zhang F, Weinberger DR. Genetic variation in CYP3A43 explains racial difference in olanzapine clearance. Mol. Psychiatry 16, 620-625 (2011).
12. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM. Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin. Pharmacokinet. 37, 177-193 (1999).
13. Bigos KL, Pollock BG, Coley KC et al. Sex, race, and smoking impact olanzapine exposure. J. Clin. Pharmacol. 48, 157-165 (2008).
14. Gex-Fabry M, Balant-Gorgia AE, Balant LP. Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication. Ther. Drug Monit. 25, 46-53 (2003).
15. Patel MX, Bowskill S, Couchman L et al. Plasma olanzapine in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1999-2009. J. Clin. Psychopharmacol. 31, 411-417 (2011).
16. Weigmann H, Gerek S, Zeisig A, Müller M, Härtter S, Hiemke C. Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: evidence from a therapeutic drug monitoring service. Ther. Drug Monit. 23, 410-413 (2001).
17. Olesen OV, Linnet K. Olanzapine serum concentrations in psychiatric patients given standard doses: the influence of comedication. Ther. Drug Monit. 21, 87-90 (1999).
18. Moons T, de Roo M, Claes S, Dom G. Relationship between P-glycoprotein and second-generation antipsychotics. Pharmacogenomics 12, 1193-1211 (2011).
19. Kassahun K, Mattiuz E, Nyhart E Jr et al. Disposition and biotransformation of the antipsychotic agent olanzapine in humans. Drug Metab. Dispos. 25, 81-93 (1997).
20. Green MD, Tephly TR. Glucuronidation of amine substrates by purified and expressed UDP-glucuronosyltransferase proteins. Drug Metab. Dispos. 26, 860-867 (1998).
21. Kassahun K, Mattiuz E, Franklin R, Gillespie T. Olanzapine 10-N-glucuronide. Drug Metab. Dispos. 26, 848-855 (1998).
22. Mattiuz E, Franklin R, Gillespie T et al. Disposition and metabolism of olanzapine in mice, dogs, and rhesus monkeys. Drug Metab. Dispos. 25, 573-583 (1997).
23. Ring BJ, Catlow J, Lindsay TJ et al. Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. J. Pharmacol. Exp. Ther. 276, 658-666 (1996).
24. Calligaro DO, Fairhurst J, Hotten TM, Moore NA, Tupper DE. The synthesis and biological activity of some known and putative metabolites of the atypical antipsychotic agent olanzapine (LY170053). Bioorg. Med. Chem. Lett. 7, 25-30 (1997).
25. Hägg S, Spigset O, Lakso HA, Dahlqvist R. Olanzapine disposition in humans is unrelated to CYP1A2 and CYP2D6 phenotypes. Eur. J. Clin. Pharmacol. 57, 493-497 (2001).
26. Cabaleiro T, Lopez-Rodriguez R, Ochoa D, Roman M, Novalbos J, Abad-Santos F. Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects. Hum. Psychopharmacol. 28, 205-214 (2013).
27. Carrillo JA, Herraiz AG, Ramos SI, Gervasini G, Vizcaino S, Benitez J. Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine. J. Clin. Psychopharmacol. 23, 119-127 (2003).
28. Nozawa M, Ohnuma T, Matsubara Y et al. The relationship between the response of clinical symptoms and plasma olanzapine concentration, based on pharmacogenetics: Juntendo University Schizophrenia Projects (JUSP). Ther. Drug Monit. 30, 35-40 (2008).
29. Skogh E, Sjodin I, Josefsson M, Dahl ML. High correlation between serum and cerebrospinal fluid olanzapine concentrations in patients with schizophrenia or schizoaffective disorder medicating with oral olanzapine as the only antipsychotic drug. J. Clin. Psychopharmacol. 31, 4-9 (2011).
30. Schweikl H, Taylor JA, Kitareewan S, Linko P, Nagorney D, Goldstein JA. Expression of CYP1A1 and CYP1A2 genes in human liver. Pharmacogenetics 3, 239-249 (1993).
31. Fuhr U, Rost KL. Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva. Pharmacogenetics 4, 109-116 (1994).
32. Kalow W, Tang BK. The use of caffeine for enzyme assays: a critical appraisal. Clin. Pharmacol. Ther. 53, 503-514 (1993).
33. Shirley KL, Hon YY, Penzak SR, Lam YWF, Spratlin V, Jann MW. Correlation of cytochrome P450 (CYP) 1A2 activity using caffeine phenotyping and olanzapine disposition in healthy volunteers. Neuropsychopharmacology 28, 961-966 (2003).
34. Sachse C, Brochmoller J, Bauer S, Roots I. Functional significance of a C-> A polymorphism in intron I of the cytochrome P450 CYP1A2 gene tested with caffeine. Br. J. Clin. Pharmacol. 47, 445-449 (1999).
35. Ghotbi R, Christensen M, Roh HK, Ingelman-Sundberg M, Aklillu E, Bertilsson L. Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans. Eur. J. Clin. Pharmacol. 63, 537-546 (2007).
36. Laika B, Leucht S, Heres S, Schneider H, Steimer W. Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome. Pharmacogenomics J. 10, 20-29 (2010).
37. Ghotbi R, Mannheimer B, Aklillu E et al. Carriers of the UGT1A4 142T>G gene variant are predisposed to reduced olanzapine exposure-an impact similar to male gender or smoking in schizophrenic patients. Eur. J. Clin. Pharmacol. 66, 465-474 (2010).
38. Söderberg MM, Haslemo T, Molden E, Dahl ML. Influence of CYP1A1/CYP1A2 and AHR polymorphisms on systemic olanzapine exposure. Pharmacogenet. Genomics 23, 279-285 (2013).
39. Cornelis MC, Monda KL, Yu K et al. Genome-wide meta-analysis identifies regions on 7p21 (AHR) and 15q24 (CYP1A2) as determinants of habitual caffeine consumption. PLoS Genet. 7, e1002033 (2011).
40. Sulem P, Gudbjartsson DF, Geller F et al. Sequence variants at CYP1A1-CYP1A2 and AHR associate with coffee consumption. Hum. Mol. Genet. 20, 2071-2077 (2011).
41. Amin N, Byrne E, Johnson J et al. Genome-wide association analysis of coffee drinking suggests association with CYP1A1/CYP1A2 and NRCAM. Mol. Psychiatry 17, 1116-1129 (2012).
42. Nebert DW, Dalton TP, Okey AB, Gonzalez FJ. Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer. J. Biol. Chem. 279, 23847-23850 (2004).
43. Linnet K. Glucuronidation of olanzapine by cDNA-expressed human UDP-glucuronosyltransferases and human liver microsomes. Hum. Psychopharmacol. 17, 233-238 (2002).
44. Erickson-Ridout KK, Zhu J, Lazarus P. Olanzapine metabolism and the significance of UGT1A448V and UGT2B1067Y variants. Pharmacogenet. Genomics 21, 539-551 (2011).
45. Kaivosaari S, Toivonen P, Hesse LM, Koskinen M, Court MH, Finel M. Nicotine glucuronidation and the human UDP-glucuronosyltransferase UGT2B10. Mol. Pharmacol. 72, 761-768 (2007).
46. Mori A, Maruo Y, Iwai M, Sato H, Takeuchi Y. UDP-glucuronosyltransferase 1A4 polymorphisms in a Japanese population and kinetics of clozapine glucuronidation. Drug Metab. Dispos. 33, 672-675 (2005).
47. Ehmer U, Vogel A, Schutte JK, Krone B, Manns MP, Strassburg CP. Variation of hepatic glucuronidation: novel functional polymorphisms of the UDP-glucuronosyltransferase UGT1A4. Hepatology 39, 970-977 (2004).
48. Benoit-Biancamano MO, Adam JP, Bernard O et al. A pharmacogenetics study of the human glucuronosyltransferase UGT1A4. Pharmacogenet. Genomics 19, 945-954 (2009).
49. Erichsen TJ, Ehmer U, Kalthoff S et al. Genetic variability of aryl hydrocarbon receptor (AhR)-mediated regulation of the human UDP glucuronosyltransferase (UGT) 1A4 gene. Toxicol. Appl. Pharmacol. 230, 252-260 (2008).
50. Mao M, Skogh E, Scordo MG, Dahl M. Interindividual variation in olanzapine concentration influenced by UGT1A4 L48V polymorphism in serum and upstream FMO polymorphisms in cerebrospinal fluid. J. Clin. Psychopharmacol. 32, 287-289 (2012).
51. Haslemo T, Loryan I, Ueda N et al. UGT1A4*3 encodes significantly increased glucuronidation of olanzapine in patients on maintenance treatment and in recombinant systems. Clin. Pharmacol. Ther. 92, 221-227 (2012).
52. Chen G, Dellinger RW, Gallagher CJ, Sun D, Lazarus P. Identification of a prevalent functional missense polymorphism in the UGT2B10 gene and its association with UGT2B10 inactivation against tobacco-specific nitrosamines. Pharmacogenet. Genomics 18, 181-191 (2008).
53. Lomri N, Gu Q, Cashman JR. Molecular cloning of the flavin-containing monooxygenase (form II) cDNA from adult human liver. Proc. Natl Acad. Sci. USA 89, 1685-1689 (1992).
54. Hernandez D, Janmohamed A, Chandan P, Phillips IR, Shephard EA. Organization and evolution of the flavin-containing monooxygenase genes of human and mouse: Identification of novel gene and pseudogene clusters. Pharmacogenetics 14, 117-130 (2004).
55. Phillips IR, Dolphin CT, Clair P et al. The molecular biology of the flavin-containing monooxygenases of man. Chem. Biol. Interact. 96, 17-32 (1995).
56. Dolphin CT, Cullingford TE, Shephard EA, Smith RL, Phillips IR. Differential developmental and tissue-specific regulation of expression of the genes encoding three members of the flavin-containing monooxygenase family of man, FMO1, FMO3 and FMO4. Eur. J. Biochem. 235, 683-689 (1996).
57. Phillips IR, Shephard EA. Flavin-containing monooxygenases: mutations, disease and drug response. Trends Pharmacol. Sci. 29, 294-301 (2008).
58. Zschocke J, Kohlmueller D, Quak E, Meissner T, Hoffmann GF, Mayatepek E. Mild trimethylaminuria caused by common variants in FMO3 gene. Lancet 354, 834-835 (1999).
59. Kang JH, Chung WG, Lee KH et al. Phenotypes of flavin-containing monooxygenase activity determined by ranitidine N-oxidation are positively correlated with genotypes of linked FMO3 gene mutations in a Korean population. Pharmacogenetics 10, 67-78 (2000).
60. Hisamuddin IM, Wehbi MA, Schmotzer B et al. Genetic polymorphisms of flavin monooxygenase 3 in sulindac-induced regression of colorectal adenomas in familial adenomatous polyposis. Cancer Epidemiol. Biomarkers Prev. 14, 2366-2369 (2005).
61. Cashman JR, Zhang J, Nelson MR, Braun A. Analysis of flavin-containing monooxygenase 3 genotype data in populations administered the anti-schizophrenia agent olanzapine. Drug Metab. Lett. 2, 100-114 (2008).
62. Söderberg MM, Haslemo T, Molden E, Dahl ML. Influence of FMO1 and 3 polymorphisms on serum olanzapine and its N-oxide metabolite in psychiatric patients. Pharmacogenomics J. doi:10.1038/tpj.2012.47. (2012) (Epub ahead of print).
63. Koukouritaki SB, Poch MT, Cabacungan ET, McCarver DG, Hines RN. Discovery of novel flavin-containing monooxygenase 3 (FMO3) single nucleotide polymorphisms and functional analysis of upstream haplotype variants. Mol. Pharmacol. 68, 383-392 (2005).
64. Hernandez D, Janmohamed A, Chandan P, Omar BA, Phillips IR, Shephard EA. Deletion of the mouse Fmo1 gene results in enhanced pharmacological behavioural responses to imipramine. Pharmacogenet. Genomics 19, 289-299 (2009).
65. Damani LA, Pool WF, Crooks PA, Kaderlik RK, Ziegler DM. Stereoselectivity in the Ń-oxidation of nicotine isomers by flavin-containing monooxygenase. Mol. Pharmacol. 33, 702-705 (1988).
66. Krueger SK, Williams DE. Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism. Pharmacol. Ther. 106, 357-387 (2005).
67. Yeung CK, Lang DH, Thummel KE, Rettie AE. Immunoquantitation of FMO1 in human liver, kidney, and intestine. Drug Metab. Dispos. 28, 1107-1111 (2000).
68. Hines RN, Luo Z, Hopp KA, Cabacungan ET, Koukouritaki SB, McCarver DG. Genetic variability at the human FMO1 locus: significance of a basal promoter yin yang 1 element polymorphism (FMO1*6 ). J. Pharmacol. Exp. Ther. 306, 1210-1218 (2003).
69. Hinrichs AL, Murphy SE, Wang JC et al. Common polymorphisms in FMO1 are associated with nicotine dependence. Pharmacogenet. Genomics 21, 397-402 (2011).
70. Westlind A, Malmebo S, Johansson I et al. Cloning and tissue distribution of a novel human cytochrome p450 of the CYP3A subfamily, CYP3A43. Biochem. Biophys. Res. Commun. 281, 1349-1355 (2001).
71. Gellner K, Eiselt R, Hustert E et al. Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. Pharmacogenetics 11, 111-121 (2001).
72. Agarwal V, Kommaddi RP, Valli K et al. Drug metabolism in human brain: high levels of cytochrome P4503A43 in brain and metabolism of anti-anxiety drug alprazolam to its active metabolite. PLoS ONE 3, e2337 (2008).
73. Corchero J, Pimprale S, Kimura S, Gonzalez FJ. Organization of the CYP1A cluster on human chromosome 15: implications for gene regulation. Pharmacogenetics 11, 1-6 (2001).
74. Ueda R, Iketaki H, Nagata K et al. A common regulatory region functions bidirectionally in transcriptional activation of the human CYP1A1 and CYP1A2 genes. Mol. Pharmacol. 69, 1924-1930 (2006).
75. 1000 Genomes Project Consortium, Abecasis GR, Auton A. An integrated map of genetic variation from 1,092 human genomes. Nature 491, 56-65 (2012).
76. Gong QH, Cho JW, Huang T et al. Thirteen UDPglucuronosyltransferase genes are encoded at the human UGT1 gene complex locus. Pharmacogenetics 11, 357-368 (2001).
77. International HapMap 3 Consortium, Altshuler DM, Gibbs RA et al. Integrating common and rare genetic variation in diverse human populations. Nature 467, 52-58 (2010).
78. Park CS, Kang JH, Chung WG et al. Ethnic differences in allelic frequency of two flavin-containing monooxygenase 3 (FMO3) polymorphisms: linkage and effects on in vivo and in vitro FMO activities. Pharmacogenetics 12, 77-80 (2002).
79. Allerston CK, Shimizu M, Fujieda M, Shephard EA, Yamazaki H, Phillips IR. Molecular evolution and balancing selection in the flavin-containing monooxygenase 3 gene (FMO3). Pharmacogenet. Genomics 17, 827-839 (2007).
80. Mao M, Matimba A, Scordo MG et al. Flavin-containing monooxygenase 3 polymorphisms in 13 ethnic populations from Europe, East Asia and sub-Saharan Africa: frequency and linkage analysis. Pharmacogenomics 10, 1447-1455 (2009).
81. Phillips IR, Francois AA, Shephard EA. The Flavin-containing monoooxygenases (FMOs): genetic variation and its consequences for the metabolism of therapeutic drugs. Curr. Pharmacogenomics 5, 292-313 (2007).
82. Furnes B, Schlenk D. Evaluation of xenobiotic N-and S-oxidation by variant flavin-containing monooxygenase 1 (FMO1) enzymes. Toxicol. Sci. 78, 196-203 (2004).
83. Bickel MH. The pharmacology and biochemistry of N-oxides. Pharmacol. Rev. 21, 325-355 (1969).